Obinna C Ubah
Overview
Explore the profile of Obinna C Ubah including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
143
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pandey S, Kovaleva M, Barelle C, Ubah O
Methods Mol Biol
. 2022 Feb;
2446:19-33.
PMID: 35157267
The approval of the first VHH-based drug caplacizumab (anti-von Willebrand factor) has validated a two-decade long commitment in time and research effort to realize the clinical potential of single-domain antibodies....
2.
Ubah O, Lake E, Gunaratne G, Gallant J, Fernie M, Robertson A, et al.
Nat Commun
. 2021 Dec;
12(1):7325.
PMID: 34916516
Single-domain Variable New Antigen Receptors (VNARs) from the immune system of sharks are the smallest naturally occurring binding domains found in nature. Possessing flexible paratopes that can recognize protein motifs...
3.
Ubah O, Porter A, Barelle C
J Immunol Res
. 2020 Feb;
2020:7283239.
PMID: 32090129
Anti-drug antibodies (ADAs), specific for biotherapeutic drugs, are associated with reduced serum drug levels and compromised therapeutic response. The impact of ADA on the bioavailability and clinical efficacy of blockbuster...
4.
Steven J, Ubah O, Buschhaus M, Kovaleva M, Ferguson L, Porter A, et al.
Methods Mol Biol
. 2019 Oct;
2070:115-142.
PMID: 31625093
VNAR domains are the binding regions of new antigen receptor proteins (IgNAR) which are unique to sharks, skates, and rays (Elasmobranchii). Individual VNAR domains can bind antigens independently and are...
5.
Pepple K, Wilson L, Van Gelder R, Kovaleva M, Ubah O, Steven J, et al.
Transl Vis Sci Technol
. 2019 Oct;
8(5):11.
PMID: 31588375
Purpose: We assess the efficacy of two next-generation biologic therapies in treating experimental autoimmune uveitis. Methods: Variable binding domains from shark immunoglobulin novel antigen receptors (VNARs) were fused with a...
6.
Ubah O, Steven J, Porter A, Barelle C
Front Immunol
. 2019 Apr;
10:526.
PMID: 30967865
Tumor necrosis factor-alpha (TNF-α), an established pro-inflammatory cytokine plays a central role in the induction and progression of several chronic inflammatory and autoimmune diseases. Targeting TNF-α as a treatment modality...
7.
Ubah O, Buschhaus M, Ferguson L, Kovaleva M, Steven J, Porter A, et al.
Biochem Soc Trans
. 2018 Nov;
46(6):1559-1565.
PMID: 30381336
Therapeutic mAbs have delivered several blockbuster drugs in oncology and autoimmune inflammatory disease. Revenue for mAbs continues to rise, even in the face of competition from a growing portfolio of...
8.
Ubah O, Steven J, Kovaleva M, Ferguson L, Barelle C, Porter A, et al.
Front Immunol
. 2018 Jan;
8:1780.
PMID: 29312310
The management of chronic inflammatory diseases, such as inflammatory bowel disease, psoriasis, and rheumatoid arthritis has significantly improved over the last decade with the clinical availability of anti-TNF-α biologics. Despite...
9.
Steven J, Muller M, Carvalho M, Ubah O, Kovaleva M, Donohoe G, et al.
Front Immunol
. 2017 Nov;
8:1361.
PMID: 29109729
Molecular engineering to increase the percentage identity to common human immunoglobulin sequences of non-human therapeutic antibodies and scaffolds has become standard practice. This strategy is often used to reduce undesirable...
10.
Ubah O, Barelle C, Buschhaus M, Porter A
Curr Pharm Des
. 2016 Sep;
22(43):6519-6526.
PMID: 27604606
Phage display technology has revolutionized the science of drug discovery by transforming the generation and manipulation of ligands, such as antibody fragments, enzymes, and peptides. The basis of this technology...